Is Boeing's New 777-9 Plane a Reason to Buy the Stock?

Boeing stock rose 7.6% for the week ended May 11 after the first Lufthansa 777-9 completed a successful full-interior test flight on May 7. The article argues the result improves the odds of first 777-9 deliveries later this year, easing concerns about a delay to 2027 and supporting the aircraft’s certification and production outlook. A potential China trip by CEO Kelly Ortberg is cited as an additional catalyst, with speculation around a possible order for 500 737 MAX jets.

Analysis

The market is starting to re-rate Boeing from a “serial execution risk” story into a “path-dependent recovery” story, and that transition matters more than the headline itself. A successful milestone on a flagship widebody program reduces the perceived probability of a long-dated delivery slip, which can compress the equity risk premium faster than the fundamental cash flow actually improves. In other words, the stock can continue to outperform for weeks or months even before the P&L impact shows up, because positioning has likely been built around disappointment rather than normalization.

The second-order beneficiary is not just BA’s commercial franchise but its supplier base and adjacent aerospace names, which tend to lag the initial move when credibility returns. If certification and first deliveries stay on track, the biggest incremental upside is in production cadence, not one-off unit economics: that improves working capital, stabilizes labor planning, and lowers the odds of another negative free-cash-flow surprise. The flip side is that any fresh slippage would be especially damaging now because the stock has started to discount a cleaner execution path; that means the next miss would hit both fundamentals and sentiment simultaneously.

The China angle is the more asymmetric catalyst, but also the most headline-driven. A meaningful order announcement would be a months-not-days event and would likely re-anchor investor expectations around long-cycle demand, yet the market may be overestimating how quickly political theater translates into signed aircraft commitments and scheduled deliveries. The real contrarian point is that even without a China order, the equity may have room to run if the company simply avoids self-inflicted delays for two or three quarters; the bar is low, and the first sustained proof of operational competence could force systematic underweights to cover.

Key risk: the move can reverse quickly if the narrative shifts from “test success” to “certification delay” or “delivery slip,” especially given how tightly the stock has traded to incremental headlines. The setup favors tactical longs, but not a blind overweight; investors are being paid to own the rebound only if they size the probability of another procedural setback as materially lower than the market did three months ago.

Key Decisions for Investors

• Tactically long BA for 4-12 weeks on pullbacks; target a continuation move as the market reprices execution risk lower, but use a tight stop if any fresh certification or delivery delay reappears.
• Pair trade: long BA / short a basket of higher-quality industrials or aerospace peers that have already de-risked, to isolate the sentiment re-rating while reducing beta to the broader market.
• Buy BA call spreads with 2-4 month expiry to express upside from a China-order headline or continued 777-9 progress; prefer defined-risk structure because the stock is still headline-sensitive.
• Add selective exposure to key aerospace suppliers on weakness if BA’s production cadence improves; the best risk/reward is in names that benefit from higher line rates without needing perfect aircraft-delivery timing.
• If BA rallies sharply on China-order speculation, fade part of the move into strength: the market may be pricing an order book outcome before it is actually committed, creating a good opportunity to monetize headline premium.